659 results on '"Zielinski C"'
Search Results
2. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
3. ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care—a tale stretching over 8 years
4. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients
5. ESMO-Magnitude of Clinical Benefit Scale version 1.1
6. COP27 Climate Change Conference: urgent action needed for Africa and the world
7. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment
8. ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
9. Un corpus multimodal pour étudier les interactions par visioconférence pour le développement des compétences techno-pédagogiques en didactique des langues et formation de formateurs
10. COP27 climate change conference: Urgent action needed for Africa and the world
11. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
12. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
13. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS)
14. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
15. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
16. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism
17. Introducing pro and con discussions in ESMO Open—Cancer Horizons
18. Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients
19. ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
20. Thrombosis risk and survival in cancer patients with elevated C‐reactive protein
21. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
22. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
23. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
24. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
25. 415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
26. P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
27. A network meta-analysis comparing the efficacy and safety of anticoagulants for the treatment of venous thromboembolism in cancer patients: OR260
28. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
29. Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormonereceptor+/HER2-metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
30. Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
31. Professor Gouri Shankar Bhattacharyya
32. Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
33. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients
34. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
35. The landscape of medical oncology in Europe by 2020†
36. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
37. Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
38. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
39. Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
40. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
41. Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)
42. PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome
43. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
44. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma
45. Biomarkers predictive of venous thromboembolism in patients with high grade gliomas: PB 3.60–2
46. Association of interleukins with venous thromboembolism and mortality in cancer patients: PA 1.16–5
47. Association of mean platelet volume with cancer-associated venous thromboembolism: results from the vienna cancer and thrombosis study (CATS): OC 31.1
48. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
49. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
50. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.